Go to content

Publications

484 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Descriptions of pharmaceutical care provisions 2012 (BR/CU- 5056) – clarification within the framework of health insurance.

    The Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa) has approved a new ‘Descriptions of pharmaceutical care ...

    Report | 29-08-2011

  2. PCA3 medical test as diagnostic intervention for prostate cancer

    CVZ has examined whether using the PCA3 gene expression test on patients with suspected prostate cancer and a negative initial ...

    Report | 22-08-2011

  3. Indications for proton therapy

    Proton therapy is regarded as an insured provision for the indications head/neck tumours, breast cancer, lung cancer and prostate ...

    Report | 22-08-2011

  4. Ranibizumab (Lucentis) for the treatment of visual impairment due to diabetic macular oedema

    Head-to-head trials have shown that, with respect to the intended and unintended effects, ranibizumab is superior to laser for ...

    Report | 25-07-2011

  5. Atomoxetine (Strattera) for the treatment of Attention Deficit Hyperactivity Disorder

    The Medicinal Products Reimbursement Committee (CFH) has carried out a re-assessment of the medicine atomoxetine (Strattera). ...

    Report | 27-06-2011

  6. Lapatinib (Tyverb) in combination with an aromatase inhibitor for the indication metastatic HR+ HER2+ breast cancer

    For postmenopausal patients with HR+ HER2+ metastatic breast cancer without rapid progression, without extensive visceral ...

    Report | 27-06-2011

  7. Amifampridine (Firdapse) for the symptomatic treatment of Lambert Eaton myasthenic syndrome (LEMS)

    For the treatment of LEMS, amifampridine phosphate has an added therapeutic value in comparison with pyridostigmine. For the ...

    Report | 27-06-2011

  8. Prevention of panic disorders

    Background reports show that for panic disorders sufficient scientific evidence exists for the efficacy of preventive ...

    Report | 27-06-2011

  9. Abarelix (Plenaxis) for the treatment of advanced hormone-dependent prostate cancer

    Data from two head-to-head trials showed that abarelix was not inferior to the GnHR-agonist leuprolide. The unintended effects of ...

    Report | 27-06-2011

  10. Retigabine (Trobalt) for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy

    As an adjunctive treatment for partial epilepsy, the therapeutic value of retigabine is comparable with that of gabapentin, ...

    Report | 27-06-2011

Go to